Universal Vision Biotechnology Co., Ltd. (TPEX:3218)
137.00
0.00 (0.00%)
Sep 8, 2026, 12:18 PM CST
TPEX:3218 Revenue
Universal Vision Biotechnology had revenue of 1.13B TWD in the quarter ending June 30, 2026, with 10.12% growth. This brings the company's revenue in the last twelve months to 4.27B, up 0.24% year-over-year. In the year 2025, Universal Vision Biotechnology had annual revenue of 4.20B, down -0.57%.
Revenue (ttm)
4.27B
Revenue Growth
+0.24%
P/S Ratio
2.72
Revenue / Employee
10.66M
Employees
401
Market Cap
11.61B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.20B | -24.22M | -0.57% |
| Dec 31, 2024 | 4.23B | 146.05M | 3.58% |
| Dec 31, 2023 | 4.08B | 588.20M | 16.83% |
| Dec 31, 2022 | 3.49B | 862.26M | 32.76% |
| Dec 31, 2021 | 2.63B | 578.66M | 28.18% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| PharmaEssentia | 20.75B |
| Grape King Bio | 10.12B |
| Excelsior Medical | 9.20B |
| TaiDoc Technology | 4.23B |
| Vizionfocus | 4.03B |
| Foresee Pharmaceuticals | 471.13M |
| ACRO Biomedical | 52.76M |
| Lumosa Therapeutics | 34.37M |